Azoulay E, Knoebl P, Garnacho-Montero J, et al. Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest. 2017;152:424-434.
Burwick RM, Fichorova RN, Dawood HY, et al. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62:1040-1045.
Burwick RM, Feinberg BB. Complement activation and regulation in preeclampsia and HELLP syndrome. Am J Obstet Gynecol. 2020. doi: 10.1016/j.ajog.2020.09.038. [Epub ahead of print].
Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34:201-203.
Burwick RM, Velásquez JA, Valencia CM, et al. Terminal complement activation in preeclampsia. Obstet Gynecol. 2018;132:1477-1485.
Caravaca-Fontán F, Lucientes L, Cavero T, et al. Update on C3 glomerulopathy: a complement-mediated disease. Nephron. 2020;144:272-280.
Daha MR, Van Es LA. Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor. Immunology. 1981;43:33-38.
Epperla N, Li A, Logan B, Fretham C, et al. Incidence, Risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol. 2020;189:1171-1181.
Fakhouri F, Fila M, Provôt F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12:50-59.
Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554-562.
Galbusera M, Noris M, Gastoldi S, et al. An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome. Am J Kidney Dis. 2019;74:56-72.
Girardi G, Lingo JJ, Fleming SD, Regal JF. Essential role of complement in pregnancy: from implantation to parturition and beyond. Front Immunol. 2020;11:1681.
Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91:539-551.
Huppertz B, Kadyrov M, Kingdom JC. Apoptosis and its role in the trophoblast. Am J Obstet Gynecol. 2006;195:29-39.
Iatropoulos P, Daina E, Curreri M, et al. Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex-mediated membranoproliferative GN. J Am Soc Nephrol. 2018;29:283-294.
Iatropoulos P, Noris M, Mele C, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131-142.
Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124:645-563.
Jodele S, Dandoy CE, Lane A, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135:1049-1057.
Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29:191-204.
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169-2181.
Li A, Wu Q, Davis C, et al. Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal. Biol Blood Marrow Transplant. 2019;25:570-576.
Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485-487.
Masson PL, Delire M, Cambiaso CL. Circulating immune complexes in normal human pregnancy. Nature. 1977;266:542-543.
Marinozzi MC, Chauvet S, Le Quintrec M, et al. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int. 2017;92:1232-1241.
Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726.
Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84:1079-1089.
Rampersad R, Barton A, Sadovsky Y, Nelson DM. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta. 2008;29:855-861.
Richani K, Romero R, Soto E, et al. Unexplained intrauterine fetal death is accompanied by activation of complement. J Perinat Med. 2005;33:296-305.
Richani K, Soto E, Romero R, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17:239-245.
Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020;97:1287-1296.
Schoettler M, Lehmann LE, Margossian S, et al. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020;4:2536-2547.
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012;366:1119-1131.
Smith SC, Baker PN, Symonds EM. Placental apoptosis in normal human pregnancy. Am J Obstet Gynecol. 1997;177:57-65.
Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15:129-143.
Socié G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185:297-310.
Tolbert VP, Dvorak CC, Golden C, et al. Risk factors for transplant-associated thrombotic microangiopathy after autologous hematopoietic cell transplant in high-risk neuroblastoma. Biol Blood Marrow Transplant. 2019;25:2031-2039.
Velasquez JA, Burwick RM, Silva JL, et al. CD59 and regulation of terminal complement in hypertensive disorders of pregnancy: The COPA II Study. SMFM's 40th Annual Pregnancy Meeting. Abstract 87
Zipfel PF, Wiech T, Rudnick R, et al. Complement inhibitors in clinical trials for glomerular diseases. Front Immunol. 2019;10:2166.

CME / ABIM MOC

The Complement Pathway and Renal Dysfunction: From Pathophysiology to Therapeutic Targets

Authors: Giuseppe Remuzzi, MD; Richard Burwick, MD, MPH; Christopher C. Dvorak, MD; Carla M. Nester, MD, MSA, FASN; Eric Rondeau, MD
CME / ABIM MOC Released: 11/18/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/18/2021, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for hem/onc specialists, nephrologists, and pediatricians.

The goal of this activity is to increase awareness and understanding about ongoing research into how targeting the complement pathway can address the underlying dysfunction in a variety of different renal disorders.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Role of the complement pathway in renal disorders
- Targets in the complement pathway for the treatment of atypical hemolytic uremic syndrome (aHUS)
- Molecular targets in the complement pathway undergoing evaluation for the prevention of preeclampsia
- Molecular targets in the complement pathway for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA)

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Giuseppe Remuzzi, MD

Professor of Nephrology
Director, Department of Immunology and Clinical Transplantation
Director, Division of Nephrology and Dialysis
Bergamo Hospital
Bergamo, Italy

Disclosures

Disclosure: Giuseppe Remuzzi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Akebia Therapeutics; Alexion Pharmaceuticals; Janssen Pharmaceuticals; Omeron
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals; Alnylam; Boehringer Ingelheim; Handok
Inc.; Inception Sciences Canada; Janssen Pharmaceuticals; Omeros
Received grants for clinical research from: Achillion Pharmaceuticals; Novartis

Richard Burwick, MD, MPH

Assistant Professor
Department of Obstetrics & Gynecology
Division of Maternal Fetal Medicine; Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Los Angeles, California, United States

Disclosures

Disclosure: Richard Burwick, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals
Received grants for clinical research from: Alexion Pharmaceuticals

Chrsitopher C. Dvorak, MD

Professor of Clinical Pediatrics
Division of Pediatric Blood and Marrow Transplantation
UCSF Benioff Children’s Hospital
San Francisco, California, United States

Disclosures

Disclosure: Christopher C. Dvorak, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals; Omeros Corp.

Carla M. Nester, MD, MSA, FASN

Jean E. Robillard MD, Chair in Pediatric Nephrology
Director, Division of Pediatric Nephrology, Dialysis and Transplantation
Associate Director, Molecular Otolaryngology and Renal Research Laboratory
Iowa City, Iowa

Disclosures

Disclosure: Carla M. Nester, MD, MSA, FASN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Achillion Pharmaceuticals; Alexion Pharmaceuticals; BioCryst; Novartis
Received grants for clinical research from: Achillion Pharmaceuticals; Alexion Pharmaceuticals; BioCryst; ChemoCentryx; Novartis; Retrophin

Eric Rondeau, MD

Professor
Sorbonne Université
Intensive Care Nephrology and Transplantation Department
Tenon Hospital
Paris, France

Disclosures

Disclosure: Eric Rondeau, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceutical
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals

Editors

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Walid Amara, MD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Servier
Served as a speaker or a member of a speakers bureau for: Amgen, Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude, Servier

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

The Complement Pathway and Renal Dysfunction: From Pathophysiology to Therapeutic Targets

Authors: Giuseppe Remuzzi, MD; Richard Burwick, MD, MPH; Christopher C. Dvorak, MD; Carla M. Nester, MD, MSA, FASN; Eric Rondeau, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/18/2020

Valid for credit through: 11/18/2021, 11:59 PM EST

processing....

Contents of This CME Activity

Clinician Handout

All sections of this activity are required for credit.

The Complement Pathway and Its Role in Renal Disorders

Dr Remuzzi discusses how the dysregulation of the complement pathway is involved in the different renal disorders.
Giuseppe Remuzzi, MD

The Complement Pathway and aHUS

Dr Rondeau discusses complement dysregulations in aHUS and their practical therapeutic implications.
Eric Rondeau, MD

The Complement Pathway and TA-TMA

Dr Dvorak discusses complement dysregulations in TA-TMA and their practical therapeutic implications.
Christopher C. Dvorak, MD

The Complement Pathway and C3 Glomerulopathy

Dr Nester discusses complement dysregulations in C3 glomerulopathy and their practical therapeutic implications.
Carla M. Nester, MD, MSA, FASN

Complement Dysregulation in Preeclampsia

Dr Burwick discusses complement dysregulation in preeclampsia.
Richard Burwick, MD, MPH

Page 1 of 6

The Complement Pathway and Its Role in Renal Disorders

CME / ABIM MOC Information

PDF Downloads

Clinician Handout

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Giuseppe Remuzzi, MD

Richard Burwick, MD, MPH

Chrsitopher C. Dvorak, MD

Carla M. Nester, MD, MSA, FASN​

Eric Rondeau, MD

Editors

Anne M. Sendaydiego, PharmD

Walid Amara, MD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC

The Complement Pathway and Renal Dysfunction: From Pathophysiology to Therapeutic Targets

Target Audience and Goal Statement

Disclosures

Faculty

Giuseppe Remuzzi, MD

Richard Burwick, MD, MPH

Chrsitopher C. Dvorak, MD

Carla M. Nester, MD, MSA, FASN​

Eric Rondeau, MD

Editors

Anne M. Sendaydiego, PharmD

Walid Amara, MD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Complement Pathway and Renal Dysfunction: From Pathophysiology to Therapeutic Targets

Contents of This CME Activity

Clinician Handout

The Complement Pathway and Its Role in Renal Disorders

The Complement Pathway and aHUS

The Complement Pathway and TA-TMA

The Complement Pathway and C3 Glomerulopathy

Complement Dysregulation in Preeclampsia

PDF Downloads

Carla M. Nester, MD, MSA, FASN

Carla M. Nester, MD, MSA, FASN